Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus SANCTURA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus SANCTURA XR.
CANTIL vs SANCTURA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic